Amgen Inc (AMGN) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Total Cash From Operating Activities Chart for Amgen Inc

Amgen Inc (AMGN) operating cash flow for FY2025 was USD 10.0B, a -13.3% change from FY2024. Amgen Inc's operating cash flow moved from USD -5.9M in 1988 to USD 10.0B in 2025 over 37 years. Operating cash flow compound annual growth rate: 5-year CAGR of -1.0%, 10-year CAGR of 0.9%, 20-year CAGR of 3.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$219.02B
Implied Share Price
$404.85
Enterprise Value
$253.16B
Revenue (TTM)
$38.09B
EBITDA
$17.57B
Profit Margin
22.95%
Trailing P/E
25.32
Forward P/E
17.33
Price/Book (MRQ)
22.62
Price/Sales (TTM)
5.75
EV/EBITDA
15.18
EV/Revenue
6.80
Dividend Yield
2.40%
Book Value
$21.62
Free Cash Flow (FY2025)
$8.10B
Free Cash Flow Yield
3.70%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.